209 related articles for article (PubMed ID: 31900919)
1. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
2. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
3. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
4. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
6. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
7. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
Han B; Mehra R; Suleman K; Tomlins SA; Wang L; Singhal N; Linetzky KA; Palanisamy N; Zhou M; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Sep; 22(9):1176-85. PubMed ID: 19465903
[TBL] [Abstract][Full Text] [Related]
8. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
Mehra R; Tomlins SA; Shen R; Nadeem O; Wang L; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM; Shah RB
Mod Pathol; 2007 May; 20(5):538-44. PubMed ID: 17334343
[TBL] [Abstract][Full Text] [Related]
10. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
12. An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.
Kedage V; Selvaraj N; Nicholas TR; Budka JA; Plotnik JP; Jerde TJ; Hollenhorst PC
Cell Rep; 2016 Oct; 17(5):1289-1301. PubMed ID: 27783944
[TBL] [Abstract][Full Text] [Related]
13. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
[TBL] [Abstract][Full Text] [Related]
14. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
[TBL] [Abstract][Full Text] [Related]
15. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
[TBL] [Abstract][Full Text] [Related]
16. Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements.
Ramanand SG; Mani RS
Adv Exp Med Biol; 2019; 1210():57-66. PubMed ID: 31900904
[TBL] [Abstract][Full Text] [Related]
17. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
[TBL] [Abstract][Full Text] [Related]
18. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
20. [TMPRSS2-ETS gene fusion in prostate cancer].
Perner S; Schmidt FH; Hofer MD; Kuefer R; Rubin M
Urologe A; 2007 Jul; 46(7):754-60. PubMed ID: 17458530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
